If left untreated, approximately 50% of patients with neuromyelitis optica
spectrum disorder (NMOSD) will develop severe disability, including wheelchair dependence
and blindness, and one-third will die within five years of
their initial attack. Therefore, continuous immunosuppressive preventive treatment should be
maintained in NMOSD cases. The two most commonly used first-line
therapies for NMOSD are azathioprine and rituximab. Rituximab is recommended
as the preferred initial therapy during the pandemic for the
following reasons: